Charles Schwab’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-29,628
| Closed | -$438K | – | 3735 |
|
|
2024
Q1 | $438K | Hold |
29,628
| – | – | ﹤0.01% | 3076 |
|
|
2023
Q4 | $397K | Hold |
29,628
| – | – | ﹤0.01% | 3157 |
|
|
2023
Q3 | $365K | Hold |
29,628
| – | – | ﹤0.01% | 3165 |
|
|
2023
Q2 | $364K | Buy |
+29,628
| New | +$370K | ﹤0.01% | 3181 |
|
|
2018
Q3 | – | Sell |
-37,520
| Closed | -$145K | – | 3176 |
|
|
2018
Q2 | $145K | Sell |
37,520
-30,584
| -45% | -$203K | ﹤0.01% | 3089 |
|
|
2018
Q1 | $432K | Sell |
68,104
-2,972
| -4% | -$24.6K | ﹤0.01% | 2771 |
|
|
2017
Q4 | $574K | Buy |
71,076
+2,578
| +4% | +$24K | ﹤0.01% | 2693 |
|
|
2017
Q3 | $784K | Buy |
68,498
+35,595
| +108% | +$374K | ﹤0.01% | 2573 |
|
|
2017
Q2 | $322K | Sell |
32,903
-22,880
| -41% | -$467K | ﹤0.01% | 2839 |
|
|
2017
Q1 | $1.35M | Buy |
55,783
+2,848
| +5% | +$71.3K | ﹤0.01% | 2329 |
|
|
2016
Q4 | $1.7M | Buy |
52,935
+2,564
| +5% | +$109K | ﹤0.01% | 2244 |
|
|
2016
Q3 | $2.52M | Sell |
50,371
-5,344
| -10% | -$222K | ﹤0.01% | 2028 |
|
|
2016
Q2 | $2.36M | Buy |
55,715
+1,053
| +2% | +$57.4K | ﹤0.01% | 1989 |
|
|
2016
Q1 | $3.6M | Buy |
54,662
+2,697
| +5% | +$141K | ﹤0.01% | 1719 |
|
|
2015
Q4 | $3.23M | Buy |
51,965
+9,778
| +23% | +$688K | ﹤0.01% | 1803 |
|
|
2015
Q3 | $2.83M | Buy |
42,187
+1,152
| +3% | +$94K | ﹤0.01% | 1855 |
|
|
2015
Q2 | $3.99M | Buy |
41,035
+2,657
| +7% | +$253K | 0.01% | 1699 |
|
|
2015
Q1 | $3.59M | Buy |
38,378
+1,735
| +5% | +$148K | 0.01% | 1724 |
|
|
2014
Q4 | $3.26M | Buy |
36,643
+2,022
| +6% | +$147K | ﹤0.01% | 1727 |
|
|
2014
Q3 | $2.39M | Buy |
34,621
+639
| +2% | +$34.1K | ﹤0.01% | 1859 |
|
|
2014
Q2 | $1.95M | Buy |
33,982
+2,708
| +9% | +$137K | ﹤0.01% | 1996 |
|
|
2014
Q1 | $1.24M | Buy |
31,274
+755
| +2% | +$32.3K | ﹤0.01% | 2175 |
|
|
2013
Q4 | $1.28M | Buy |
30,519
+2,570
| +9% | +$74.5K | ﹤0.01% | 2148 |
|
|
2013
Q3 | $858K | Buy |
27,949
+7,065
| +34% | +$247K | ﹤0.01% | 2283 |
|
|
2013
Q2 | $1.14M | Buy |
+20,884
| New | +$915K | ﹤0.01% | 2084 |
|
Other funds holding MACK
RA
JC
Charles Schwab's MACK Position: Q2 2024 in Review
Charles Schwab sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 29,628 shares — an estimated $438K sold.
Charles Schwab first reported a position in MACK in Q2 2013 and held it in 25 quarters. The position peaked at $3.99M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Charles Schwab reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Charles Schwab sold 29,628 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $438K.
- Charles Schwab first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Charles Schwab's Merrimack Pharmaceuticals, Inc. position peaked at $3.99M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.